Homocysteinylated protein levels in internal mammary artery (IMA) fragments and its genotype-dependence. S-Homocysteine-induced methylation modifications in IMA and aortic fragments

[1]  Xinli Hu,et al.  Dimethylarginine Dimethylaminohydrolase-1 Is the Critical Enzyme for Degrading the Cardiovascular Risk Factor Asymmetrical Dimethylarginine , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[2]  C. Wiuf,et al.  Quality assessment of DNA derived from up to 30 years old formalin fixed paraffin embedded (FFPE) tissue for PCR-based methylation analysis using SMART-MSP and MS-HRM , 2009, BMC Cancer.

[3]  K. Channon,et al.  MTHFR 677 C>T Polymorphism Reveals Functional Importance for 5-Methyltetrahydrofolate, Not Homocysteine, in Regulation of Vascular Redox State and Endothelial Function in Human Atherosclerosis , 2009, Circulation.

[4]  P. Laird,et al.  The methylenetetrahydrofolate reductase C677T mutation induces cell‐specific changes in genomic DNA methylation and uracil misincorporation: A possible molecular basis for the site‐specific cancer risk modification , 2009, International journal of cancer.

[5]  Toshiko Tanaka,et al.  Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. , 2009, American journal of human genetics.

[6]  J. Cooke,et al.  Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. , 2008, American journal of physiology. Heart and circulatory physiology.

[7]  Shu-ren Wang,et al.  Dysfunction of endothelial NO system originated from homocysteine-induced aberrant methylation pattern in promoter region of DDAH2 gene. , 2007, Chinese medical journal.

[8]  M. Formato,et al.  Factors affecting S-homocysteinylation of LDL apoprotein B. , 2006, Clinical chemistry.

[9]  J. Köllermann,et al.  Promoter Hypermethylation Profile of Kidney Cancer with New Proapoptotic p53 Target Genes and Clinical Implications , 2006, Clinical Cancer Research.

[10]  N. D. De Santo,et al.  Increased plasma protein homocysteinylation in hemodialysis patients. , 2006, Kidney international.

[11]  Christian B. Woods,et al.  Analysis of repetitive element DNA methylation by MethyLight , 2005, Nucleic acids research.

[12]  S. Tyagi,et al.  Mechanisms of homocysteine-induced oxidative stress. , 2005, American journal of physiology. Heart and circulatory physiology.

[13]  J. Fish,et al.  Epigenetic Basis for the Transcriptional Hyporesponsiveness of the Human Inducible Nitric Oxide Synthase Gene in Vascular Endothelial Cells1 , 2005, The Journal of Immunology.

[14]  J. Fish,et al.  The Expression of Endothelial Nitric-oxide Synthase Is Controlled by a Cell-specific Histone Code* , 2005, Journal of Biological Chemistry.

[15]  Zhi-yuan Yu,et al.  Hypermethylation of the Inducible Nitric-oxide Synthase Gene Promoter Inhibits Its Transcription* , 2004, Journal of Biological Chemistry.

[16]  P. Vallance,et al.  Cardiovascular Biology of the Asymmetric Dimethylarginine:Dimethylarginine Dimethylaminohydrolase Pathway , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[17]  J. Sass,et al.  S-homocysteinylation of transthyretin is detected in plasma and serum of humans with different types of hyperhomocysteinemia. , 2003, Biochemical and biophysical research communications.

[18]  J. Cooke,et al.  Endothelial Dysfunction Induced by Hyperhomocyst(e)inemia: Role of Asymmetric Dimethylarginine , 2003, Circulation.

[19]  B. Buxton,et al.  The resistance of the IMA to atherosclerosis might be associated with its higher eNOS, ACE and ET-A receptor immunoreactivity. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[20]  I. Pogribny,et al.  Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. , 2002, The Journal of nutrition.

[21]  P. Tsao,et al.  Homocysteine Impairs the Nitric Oxide Synthase Pathway: Role of Asymmetric Dimethylarginine , 2001, Circulation.

[22]  S. Sengupta,et al.  Albumin Thiolate Anion Is an Intermediate in the Formation of Albumin-S–S-Homocysteine* , 2001, The Journal of Biological Chemistry.

[23]  N. Sivasubramanian,et al.  Homocysteine Induces Expression and Secretion of Monocyte Chemoattractant Protein-1 and Interleukin-8 in Human Aortic Endothelial Cells: Implications for Vascular Disease , 2001, Circulation.

[24]  W. Ambrosius,et al.  Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis , 2001, FEBS letters.

[25]  M. Goligorsky,et al.  Effects of homocysteine on endothelial nitric oxide production. , 2000, American journal of physiology. Renal physiology.

[26]  B. Horne,et al.  Plasma Homocysteine Predicts Mortality Independently of Traditional Risk Factors and C-Reactive Protein in Patients With Angiographically Defined Coronary Artery Disease , 2000, Circulation.

[27]  M. Fox,et al.  Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. , 2000, Genomics.

[28]  H. Jakubowski.  Translational Incorporation of S-Nitrosohomocysteine into Protein* , 2000, The Journal of Biological Chemistry.

[29]  H. Jakubowski.  Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  G. E. Green,et al.  Coronary bypass surgery with internal-thoracic-artery grafts--effects on survival over a 15-year period. , 1996, The New England journal of medicine.

[31]  M. Norusis,et al.  Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. , 1991, American journal of human genetics.

[32]  P. Froguel,et al.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. , 1997, The Journal of clinical investigation.

[33]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.